About Enovis Corporation
https://www.enovis.comEnovis Corporation operates as a medical technology company worldwide.
CEO
Damien McDonald
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-04-05 | Reverse | 1:3 |
ETFs Holding This Stock
Summary
Showing Top 3 of 164
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Canaccord Genuity
Buy
UBS
Buy
Needham
Buy
JMP Securities
Market Outperform
Evercore ISI Group
Outperform
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:8.88M
Value:$215.45M
VANGUARD GROUP INC
Shares:6.52M
Value:$158.34M
BLACKROCK INC.
Shares:5.43M
Value:$131.72M
Summary
Showing Top 3 of 312
About Enovis Corporation
https://www.enovis.comEnovis Corporation operates as a medical technology company worldwide.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $548.91M ▼ | $899.79M ▲ | $-571.15M ▼ | -104.05% ▼ | $-10.06 ▼ | $-477.82M ▼ |
| Q2-2025 | $564.54M ▲ | $351.49M ▼ | $-36.74M ▲ | -6.51% ▲ | $-0.64 ▲ | $55.19M ▲ |
| Q1-2025 | $558.83M ▼ | $379M ▼ | $-55.97M ▲ | -10.01% ▲ | $-0.99 ▲ | $23.27M ▲ |
| Q4-2024 | $560.98M ▲ | $972.27M ▲ | $-703.34M ▼ | -125.38% ▼ | $-12.05 ▼ | $-590.25M ▼ |
| Q3-2024 | $505.22M | $318.2M | $-31.52M | -6.24% | $-0.57 | $39.69M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $33.62M ▼ | $4.43B ▼ | $2.41B ▼ | $2.02B ▼ |
| Q2-2025 | $44.07M ▲ | $5.02B ▲ | $2.44B ▲ | $2.58B ▼ |
| Q1-2025 | $38.46M ▼ | $4.88B ▲ | $2.25B ▲ | $2.62B ▲ |
| Q4-2024 | $48.17M ▲ | $4.72B ▼ | $2.15B ▼ | $2.56B ▼ |
| Q3-2024 | $35.42M | $5.55B | $2.22B | $3.33B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-570.91M ▼ | $82.58M ▲ | $-56.06M ▼ | $-36.91M ▼ | $-10.46M ▼ | $29.09M ▲ |
| Q2-2025 | $-36.65M ▲ | $47.77M ▲ | $-49.8M ▲ | $6.23M ▼ | $5.61M ▲ | $3.4M ▲ |
| Q1-2025 | $-55.7M ▲ | $-1.6M ▼ | $-60.52M ▼ | $51.19M ▲ | $-9.71M ▼ | $-44.86M ▼ |
| Q4-2024 | $-703.2M ▼ | $88.33M ▲ | $-57.88M ▲ | $-20.08M ▼ | $8.37M ▲ | $35.14M ▲ |
| Q3-2024 | $-31.26M | $53.56M | $-58.42M | $-148K | $-3.63M | $2.37M |
Revenue by Products
| Product | Q2-2021 | Q4-2021 | Q3-2021 | Q1-2022 |
|---|---|---|---|---|
 Fabrication Technology | $630.00M ▲ | $620.00M ▼ | $610.00M ▼ | $650.00M ▲ |
 Medical Technology | $360.00M ▲ | $400.00M ▲ | $360.00M ▼ | $380.00M ▲ |
Revenue by Geography
| Region | Q2-2012 | Q4-2012 | Q3-2012 |
|---|---|---|---|
 Foreign | $860.00M ▲ | $780.00M ▼ | $780.00M ▲ |
 UNITED STATES | $190.00M ▲ | $240.00M ▲ | $180.00M ▼ |
CEO
Damien McDonald
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-04-05 | Reverse | 1:3 |
ETFs Holding This Stock
Summary
Showing Top 3 of 164
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Canaccord Genuity
Buy
UBS
Buy
Needham
Buy
JMP Securities
Market Outperform
Evercore ISI Group
Outperform
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:8.88M
Value:$215.45M
VANGUARD GROUP INC
Shares:6.52M
Value:$158.34M
BLACKROCK INC.
Shares:5.43M
Value:$131.72M
Summary
Showing Top 3 of 312